Skip to content
Search

Latest Stories

FEATURE: Is technology the silver bullet for pharmacy?

Gary Paragpuri explains how there is more to technology and automation in pharmacy than just the shiny exteriors…

Back in 1982, a phrase began appearing in the sports sections of newspapers across the US to describe those dramatic moments in games where a particular decision or move made a significant impact. They became known as ‘game-changers’.


This logical and snappy expression, whose origins were traced by William Safire of The New York Times, was quickly picked up by those beyond the world of sport as a more general way of describing important shifts in direction.

It was soon heard in the worlds of politics and business, and also became an established part of the language of the technology community, used to describe those shiny new products that represented a quantum leap forward in terms of capability and performance.

Tackling tech misperceptions

Today, the idea that a single piece of hardware or software has the potential to transform a particular aspect of how we live or work retains a strong appeal. Any solution that can provide a simple, instant answer to complex problems is an understandably attractive concept.

Sadly, it is one of the many misperceptions that exist around technology and how it should be embedded within a business for greatest effect. At Hub and Spoke Innovations, we frequently experience this in our conversations with independent pharmacies about the potential of the Pharmaself24 collection point.

At the risk of generalising, those conversations fall largely into two main camps.

On the one hand, there are those pharmacists with the vision to see beyond the product itself – their sense of its value and their interpretation of the word ‘investment’ are based on a long-term view of the benefits they wish to bring to their patients.

On the other hand, there are those who struggle to see it as anything more than a machine, framing it in terms of a one-off purchase or a possible quick win rather than as something to be incorporated into an expanded patient offering.

Of course, this makes sense on the surface. Pharmacists are facing headwinds right now and must work hard to ensure that every penny is fully justified at a time when margins are wafer thin.

At the same time, the tendency to take a short-term view also speaks to the success many contractors have seen in adopting a tactical approach to financial control, keeping a tight rein on costs and exploiting favourable buying opportunities as they arise. In this scenario, however, there is a risk that many are either failing to see – or, perhaps, actively avoiding seeing – the big picture for their business at a more strategic level.

Even more difficult to see is the bigger picture that is playing out beyond a pharmacy’s four walls and its local area as the sector continues to experience change at a more fundamental level.

Whether it’s evolution or revolution depends on your perspective, but there is no doubt that it is here and only likely to accelerate.

The coming of the Digital Age

Pharmacy2U, the UK’s first internet pharmacy, turns 21 this year and data is available to show that it is truly coming of age. The company now dispenses close to a million items per month and that number is steadily on the rise as it looks to acquire a greater share of the available market.

In recent years, major multiples have also underlined their commitment to serving patients online, with Echo from Lloydspharmacy fast approaching half a million items per month.

In addition, there have been a raft of digitally focused entrants into the market, such as Phlo Digital Pharmacy, and HubRx, which claims to be developing “the UK’s first state of-the-art centralised automated pharmacy for independent pharmacy contractors”.

While these innovators may have technology in common, at their root, they are developments that answer some of the macro trends at play, such as the need to modernise the dispensing model and the changing expectations of 21st Century patients.

As of this year, you can also add Covid-19 to the list of forces driving change in pharmacy. While it’s fair to say that the virus remains a relatively unknown quantity, with no way to measure its ultimate impact, there are strong signs that its influence on patient behaviour will be felt for the foreseeable future.

The latest available footfall figures for non-food stores released by Ipsos Retail Performance, for example, showed that while average weekly shopper numbers in July were 13 per cent higher than June, they were down by 53.0 per cent year-on-year.

This dramatic figure can be explained in part by the ongoing observation of social distancing measures and footfall will continue to rise as people ease their way out of lockdown, but there is also more going on beneath the surface.

Dr. Tim Dension, director of Retail Intelligence, labelled it a “nervous and hesitant return” and described consumers as “understandably anxious about their safety and re-wired to prefer shopping online” – all of which has clear implications for contractors.

It can be argued, therefore, that the existing forces already changing the rules of the game for pharmacy have now been joined by a genuine game changer in Covid-19.

The sector finds itself at an inflection point, and no single technology will provide the answer, but embedding greater levels of automation over the long-term will be crucial to deliver the support contractors need as they adapt to become patient-centric, cost-efficient healthcare providers fit for tomorrow’s world.

Gary Paragpuri is CEO of Hub & Spoke Innovations Ltd.

This feature also appears in the print edition of Pharmacy Business/Oct 2020.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less